Apoptosis and the response to anticancer therapy

Current Opinion in Oncology

Volumn 13, Issue 6, 2001, Pages 453-462

  Mow, Benjamin M F ^a   Blajeski, April L ^a   Chandra, Joya ^a   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 3; CASPASE 6; CASPASE 8; CASPASE 9; CISPLATIN; CYTOCHROME C; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; RAS PROTEIN; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; CANCER THERAPY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0034765627     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200111000-00007     Document Type: Review

References (150)

1. Cell death: The significance of apoptosis
2. Apoptosis in the pathogenesis and treatment of disease
3. Apoptotic pathways: Paper wraps stone blunts scissors
4. Apoptosis in cancer: Cause and cure
5. Proliferation, cell cycle and apoptosis in Cancer
6. Apoptosis and the dilemma of cancer chemotherapy
7. Induction of apoptosis by cancer chemotherapy
8. Dysregulation of apoptosis in cancer
9. Death by a thousand cuts: An ever increasing list of caspase substrates
10. Mammalian cspases: Structure, activation, substrates and functions during apoptosis
11. A Caspase-actived DNase that degrades DNA during apoptosis, and its inhibitor ICAD
12. Biochemical pathways of caspase activation during apoptosis
13. Apoptosis signaling by death receptors
14. Apoptosis control by death and decoy receptors
15. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations
16. Caspase Activation: The induced-proximity model
17. Death-effector filaments: Novel cytoplasmic structures that recruit caspases and trigger apoptosis
18. Two CD95 (APO-1)/Fas) signaling pathways
19. Mitochondria and apoptosis
20. Mitochondria as the central control point of apoptosis
21. Mitochondrial control of cell death
22. Pro-apoptotic cascade activates BID, which oligomerizes BAK and BAX into pores that result in the release of cytochrome C
23. Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2
24. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane
25. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome C
26. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells
27. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity
28. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis
29. PUMA induces the rapid apoptosis of colorectal cancer cells
30. Caspase-9 and APAF-1 form an active holoenzyme
31. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta
32. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells
33. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
34. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1
35. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs
36. Regulation of FasL by NK-κB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells
37. Does "death receptor" signaling play a role in tumorigenesis and cancer therapy?
38. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells
39. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system
40. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
41. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: Evidence for independent mechanisms of caspase activation
42. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
43. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis
44. Mitochondrial cytochrome C release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization
45. Characterization of caspase processing and activation of HL-60 cell cytosol under cell-free conditions: Nucleotide requirement and inhibitor profile
46. The role of Apaf-1, caspase-9, and BID proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis
47. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells
48. Effects of the Bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
49. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
50. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally
51. Cytochrome C deficiency causes embryonic lethality and attenuates stress-induced apoptosis
52. Apaf1 is required for mitochondrial pathways of apoptosis and brain development
53. Differential requirement for caspase 9 in apoptotic pathways in vivo
54. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9
55. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome C release
56. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases
57. Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak
58. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice
59. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes
60. Caspase-3 is required for DNA fragmentation and morphologic changes associated with apoptosis
61. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis
62. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells
63. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis
64. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
65. Safety and antitumor activity of recombinant soluble Apo2 ligand
66. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains
67. Phosphorylation-based signaling in Fas receptor-mediated apoptosis
68. Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line
69. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death
70. BCL-2 family members and the mitochondria in apoptosis
71. TNF-alpha signals apoptosis through a Bid-dependent conformational change in Bax that is inhibited by E1B 19K
72. Constitutive activation of stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
73. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
74. STAT proteins: Novel molecular targets for cancer drug discovery
75. Bcl-2 phosphorylation required for anti-apoptosis function
76. A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis
77. Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1
78. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-XL
79. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
80. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
81. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A
82. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155
83. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival
84. Regulation of cell death protease caspase-9 by phosphorylation
85. Akt/protein kinase B inhibits cell death by preventing the release of cytochrome C from mitochondria
86. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor
87. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor Cells
88. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation
89. The inhibitors of apoptosis (IAPs) and their emerging role in cancer
90. IAP family proteins-suppressors of apoptosis
91. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
92. X-linked IAP is a direct inhibitor of cell-death proteases
93. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases
94. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases
95. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP
96. Structural basis of caspase-7 inhibition by XIAP
97. Structural basis of caspase inhibition by XIAP: Differential roles of the linker versus the BIR domain
98. Structural basis for the inhibition of caspase-3 by XIAP
99. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli
100. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspase 3 and 7
101. Inhibition of TNF-induced apoptosis by NF-kappa B
102. DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9
103. Cell death inhibition: Keeping caspases in check
104. Smac, a mitochondrial protein that promotes cytochrome C-dependent caspase activation by eliminating IAP inhibition
105. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
106. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes
107. Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins
108. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage
109. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways
110. Direction inhibition of caspase 3 is dispensable for the anti-apoptotic activity of XIAP
111. Survivin does not inhibit caspase-3 activity
112. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype
113. An exegesis of IAPs: Salvation and surprises from BIR motifs
114. BIRinging chromosomes through cell division-and survivin' the experience
115. Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes
116. Immunohistochemical analysis of interleukin-1 beta·converting enzyme/Ced- 3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease
117. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia
118. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia
119. Expression of apoptosis-controlling proteins in acute leukemia cells
120. Evaluation of the prognostic significance of Apaf-1 and caspases -2, -3, -7, -8 and -9 in acute leukemia
121. Relation between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer
122. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a Bcl-2 independent anti-apoptotic program
123. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
124. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma
125. Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway
126. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
127. Resistance to TRAIL-Induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression
128. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
129. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
130. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression
131. Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma
132. L, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas
133. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death
134. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse
135. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
136. Differential expression of MMAC/PTEN in glioblastoma multiforme: Relation to localization and prognosis
137. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations
138. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage
139. Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy
140. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma
141. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
142. The cancer anti-apoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression
143. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
144. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia
145. Prognostic significance of survivin expression in diffuse large B-cell lymphomas
146. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
147. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers
148. Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy
149. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias
150. Apoptosis and drug response